Beyond the Basics: Systemic Treatment for Atopic Dermatitis and Evaluation of Infantile Hemangiomas
Infantile Hemangiomas To kick off ODAC 2021, Dr. Yasmine Kirkorian, MD, tackled two clinical dilemmas that are frequently seen among pediatric patients in the dermatology office: poorly controlled atopic dermatitis and infantile hemangiomas. Dr. Kirkorian reviewed currently available systemic therapies for atopic dermatitis as well those in the drug development pipeline. She went into detail about how she utilizes he …
Infantile Hemangiomas
Easing the Management of Atopic Dermatitis
Atopic DermatitisDr. Friedman, jack of many trades, Professor and Interim Chair of Dermatology at George Washington University provided an excellent overview of ways to achieve victory over atopic dermatitis (AD). This expert discussion took place during the ODAC Inflammatory Diseases Symposium on December 3, 2020. How could we possibly cover atopic dermatitis in 20 minutes? Well, Dr. Friedman skillfully led us …
Atopic Dermatitis
JDD October Issue Highlights: Special Focus on Atopic Dermatitis
The October issue of the Journal of Drugs in Dermatology focuses on the topic of Atopic Dermatitis featuring an outstanding line-up of original articles. Straight from the JDD Editor's desk, we share this month's issue highlights: Clinical Relevance of Skin Pain in Atopic Dermatitis discusses the clinical relevance of skin pain with respect to its experience, pathophysiology, relationship with …
Coronavirus & Atopic Dermatitis Reporting Registry
SECURE-ADEPI Health has graciously supported the COVID-19 News and Resource Center. SECURE-AD (Surveillance Epidemiology of Corona Virus (COVID-19) Under Research Exclusion - Atopic Dermatitis) is a secure, online, de-identified international reporting registry for health care providers to report outcomes of COVID-19 in atopic dermatitis (AD) patients. Clinicians worldwide are encouraged to report al …
SECURE-AD
Consensus Recommendations on Adjunctive Topical Management of Atopic Dermatitis
  Supported by La Roche-Posay     This program will provide an overview of AD including prevalence, severity, and disease course/progression, succinct summaries of pathophysiology and medical management, and discussion of epidermal barrier dysfunction and skin microbiome shifting associated with AD. Additional emphasis is placed on adjunctive topical skin barrier app …
error

Enjoy this blog? Please spread the word :)